
- /
- Supported exchanges
- / US
- / CDXS.NASDAQ
Codexis Inc (CDXS NASDAQ) stock market data APIs
Codexis Inc Financial Data Overview
Codexis, Inc., discovers, develops, enhances, and commercializes novel enzymes and other classes of proteins. The company is a provider of enzymatic solutions for therapeutics manufacturing and leveraging proprietary CodeEvolver evolution technology platform. The CodeEvolver platform technology develops enzymes for the synthesis of RNAi therapeutics through ECO Synthesis manufacturing platform. It also develops enzymes; and 450 RNAi therapeutic assets that are in Phase 2 and Phase 3 clinical trials that targets large disease indications such as Alzheimer's, hyperlipidemia and hypertension. The company has a licensing agreement with Aldevron LLC ("Aldevron"), a manufacture of plasmid DNA, RNA and proteins; and a license agreement whereby Pfizer obtained a license to make a specific Codexis enzyme for use in the manufacture of Pfizer's products. Codexis, Inc. was incorporated in 2002 and is headquartered in Redwood City, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Codexis Inc data using free add-ons & libraries
Get Codexis Inc Fundamental Data
Codexis Inc Fundamental data includes:
- Net Revenue: 59 345 K
- EBITDA: -53 408 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-26
- EPS/Forecast: -0.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Codexis Inc News

Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announce...


Codexis Announces New Employment Inducement Grants
Codexis, Inc. REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, t...

When Will Codexis, Inc. (NASDAQ:CDXS) Become Profitable?
We feel now is a pretty good time to analyse Codexis, Inc.'s (NASDAQ:CDXS) business as it appears the company may be on the cusp of a considerable accomplishment. Codexis, Inc. discovers, develops, an...

Codexis Inc (CDXS) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Revenue Growth ...
Total Revenue (Q4 2024): $21.5 million Product Revenue (Q4 2024): $9.8 million R&D Revenue (Q4 2024): $11.6 million Annual Revenue (2024): $59.3 million (excluding PAXLOVID) Product Gross Margin (Q4 2...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.